研究目的
Assessing the potential use of urine autofluorescence analysis in the diagnostics and screening of ovarian cancer.
研究成果
CMSS analysis of urine provides a promising alternative for ovarian cancer screening method development and could be used as a diagnostic test to detect the recurrence of the disease after therapy. The method showed high sensitivity and specificity in distinguishing malignant tumors from healthy samples, though discrimination between benign and malignant tumors was less effective.
研究不足
The discrimination between benign and malignant ovarian tumors was weaker compared to distinguishing malignant tumors from healthy samples. The study suggests that different fluorescent metabolites may prevail at different stages of the disease, indicating potential areas for further optimization.
1：Experimental Design and Method Selection:
Synchronous fluorescence spectra with a 70 nm wavelength difference were recorded for various urine dilutions. Concentration matrices of synchronous spectra (CMSS) were used to classify samples into tested groups.
2：Sample Selection and Data Sources:
Urine samples from 42 healthy volunteers, 35 patients with benign ovarian tumors, and 36 patients with malignant ovarian tumors were analyzed.
3：List of Experimental Equipment and Materials:
LS45 (PerkinElmer) luminescence spectrometer, ultra micro quartz cuvette.
4：Experimental Procedures and Operational Workflow:
Urine samples were centrifuged, and supernatants were used for spectral analysis. Synchronous fluorescence spectra were collected in the excitation wavelength range 250 – 550 nm.
5：Data Analysis Methods:
Classification of the samples was made using a logistic regression model. Training of the model was carried out using the Weka software.
独家科研数据包，助您复现前沿成果，加速创新突破
获取完整内容
